Skip to main content

Free patient guide · 19 pages · PDF

Stem Cell Therapy for Angina: A Patient's Guide

Restoring Cardiac Blood Flow and Reducing Chest Pain

· Medically reviewed by SCL Medical Team

What is inside this guide

  1. Understanding Angina
  2. How Stem Cell Therapy Helps
  3. Treatment at StemCell Longevita
  4. Results & Recovery
  5. Getting Started

Chapter 1

Understanding Angina

What Is Angina?

Angina is chest pain or discomfort caused by reduced blood flow to the heart muscle (myocardial ischemia). It is not a disease itself but a symptom of underlying coronary artery disease. Angina affects approximately 10

  • million people in the United States alone. Refractory angina — chest pain that persists despite optimal medical
  • therapy and revascularization — is particularly debilitating.

Types and Symptoms

Symptoms include chest pressure, squeezing, or burning sensation, often radiating to the arm, jaw, or back. Patients with refractory angina have limited treatment options. Stem cell therapy offers hope by promoting new blood vessel formation (angiogenesis) in the heart, creating natural bypass pathways around blocked arteries.

  • Stable angina — Predictable chest pain triggered by physical exertion or emotional stress, relieved by rest or nitroglycerin.
  • Unstable angina — Unpredictable chest pain that occurs at rest or with minimal exertion, indicating worsening coronary disease.
  • Refractory angina — Persistent angina despite maximum medical therapy and when revascularization (stenting/bypass) is not feasible or has failed.

Chapter 2

How Stem Cell Therapy Helps

Cardiac Angiogenesis

MSCs promote the formation of new blood vessels (angiogenesis) and the enlargement of existing collateral vessels (arteriogenesis) in the ischemic heart. They secrete vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and other angiogenic factors that create new pathways for blood to reach oxygen- deprived heart muscle. This natural bypass effect reduces ischemia and angina symptoms. Clinical trials in refractory angina patients have demonstrated significant reductions in angina frequency (55%), increased exercise tolerance, and improved myocardial perfusion on stress testing following MSC therapy.

Clinical Evidence

55%
Reduced Angina Episodes
47%
Increased Exercise Time
78%
Improved Quality of Life

Figures reported in our own patient guide from published studies and our clinical experience. They describe groups of patients, not a prediction for any individual case. See the evidence we rely on.

Chapter 3

Treatment at StemCell Longevita

Our Angina Protocol

We use high-dose IV infusion of MSCs specifically selected for their angiogenic potential. Treatment is administered over multiple sessions with continuous cardiac monitoring. For patients with identifiable ischemic territories, targeted intracardiac delivery may be considered in coordination with our interventional cardiology team at Liv Hospital.

Treatment at Liv Hospital Ulus

  • Day 1 — Comprehensive cardiac evaluation including ECG, echocardiography, stress testing, and coronary angiography review.
  • Day 2-4 — Sequential IV stem cell infusions with cardiac monitoring.
  • Day 5 — Post-treatment cardiac assessment and discharge with follow-up plan.

Chapter 4

Results & Recovery

Expected Improvements

Angina frequency typically decreases within 4 to 8 weeks. Exercise tolerance improves over 2 to 4 months. Myocardial perfusion improvements may be documented on stress testing at 3 to 6 months. Many patients report significantly improved quality of life and reduced dependence on nitroglycerin.

4-8
Weeks to Symptom Improvement
73%
Reduced Nitroglycerin Use
18+
Months of Sustained Benefits

Figures reported in our own patient guide from published studies and our clinical experience. They describe groups of patients, not a prediction for any individual case. See the evidence we rely on.

Chapter 5

Getting Started

Next Steps

If you suffer from angina, particularly refractory angina where conventional treatments have not provided adequate relief, contact us with your cardiac imaging and treatment history for a free evaluation.

Frequently asked questions

Yes, this is one of the primary indications for cardiac stem cell therapy. Patients with refractory angina who cannot undergo further revascularization may benefit significantly from the angiogenic effects of MSC therapy.

Yes, when administered by experienced cardiac specialists with appropriate monitoring. Multiple clinical trials have confirmed the safety of MSC therapy in patients with advanced coronary disease.

The goals overlap but differ in focus. Angina treatment primarily aims to improve blood supply (angiogenesis), while heart failure treatment focuses on improving heart muscle function. Both conditions can benefit from MSC therapy.

Yes, continue all cardiac medications as prescribed. Stem cell therapy is complementary to optimal medical therapy and may allow dose adjustments over time as symptoms improve.

Next steps

Download the full guide for the complete chapters, clinical detail and the questions to ask any clinic. Our team reviews every enquiry personally and will tell you honestly whether this therapy is appropriate for your case.

Medical disclaimer

This guide is provided for educational purposes only and is not medical advice, diagnosis or treatment. Outcomes vary between individuals and no specific result is guaranteed. Always consult a qualified healthcare professional before making medical decisions.